Expert Outlook: Integra Lifesciences Through The Eyes Of 8 Analysts
Portfolio Pulse from Benzinga Insights
Integra Lifesciences (NASDAQ:IART) has been analyzed by 8 analysts, showing a range of opinions from bullish to bearish. Recent ratings indicate a shift towards bearish sentiment, with a decline in the average 12-month price target. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Despite a strong revenue growth rate, Integra's market capitalization is below industry benchmarks.
August 22, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Integra Lifesciences has experienced a shift in analyst sentiment towards bearish, with a decline in the average 12-month price target from $28.86 to $26.88. Analysts have adjusted their ratings and price targets, reflecting concerns over market conditions and company performance.
The article highlights a shift in analyst sentiment towards bearish for Integra Lifesciences, with a decrease in the average price target. This suggests potential short-term downward pressure on the stock price as analysts adjust their expectations based on market conditions and company performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100